Alternatives to Etanercept If You Can't Fill Your Prescription

Etanercept (Enbrel) has been a cornerstone of treatment for rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis for decades. But access barriers — insurance prior authorization denials, specialty pharmacy delays, or the staggering out-of-pocket cost — sometimes mean patients can't get it when they need it.

The good news: there are solid alternatives. Before switching, always work with your rheumatologist or dermatologist — any change in a biologic regimen requires careful medical oversight. But being informed about your options puts you in a much stronger position for that conversation.

Other TNF Inhibitors: The Closest Alternatives

Etanercept belongs to the TNF inhibitor class. Other drugs in this class work by a similar mechanism — blocking TNF-alpha — and are approved for many of the same conditions. These are typically the first alternatives your doctor will consider.

Adalimumab (Humira) and Its Biosimilars

Adalimumab (Humira) is the most-prescribed biologic in the world and shares many of etanercept's approved indications: RA, PsA, AS, and plaque psoriasis. Unlike etanercept, Humira's patent has expired and more than a dozen FDA-approved biosimilars are now available in the US — including Hadlima, Hyrimoz, Cyltezo, Yusimry, and others — at significantly lower list prices.

Key differences: adalimumab is a fully human monoclonal antibody (vs. a fusion protein like etanercept), it's dosed every 2 weeks rather than weekly, and it covers additional indications like Crohn's disease, ulcerative colitis, and hidradenitis suppurativa that etanercept does not. For patients facing access issues with etanercept, an adalimumab biosimilar may be substantially more affordable.

Infliximab (Remicade) and Its Biosimilars

Infliximab (Remicade) is another TNF inhibitor approved for RA, PsA, AS, and plaque psoriasis — plus Crohn's disease and ulcerative colitis. It's given as an IV infusion in a clinic every 6-8 weeks, which is a meaningful difference from etanercept's self-administered weekly injection. Multiple biosimilars (Inflectra, Renflexis, Avsola) are available. The IV clinic setting can actually simplify access for some patients.

Certolizumab Pegol (Cimzia) and Golimumab (Simponi)

Certolizumab pegol (Cimzia) is a PEGylated TNF inhibitor fragment approved for RA, PsA, AS, and nr-axSpA. It has the distinction of being considered lower-risk for fetal exposure, making it a preferred option for patients who are pregnant or planning pregnancy. Golimumab (Simponi) is a monthly self-injection approved for RA, PsA, and AS.

Non-TNF Biologics: When TNF Inhibitors Don't Work

If TNF inhibitors aren't working or can't be used, your doctor may recommend a different class of biologic:

Abatacept (Orencia) — T-cell co-stimulation modulator; approved for RA and JIA; available as weekly self-injection or monthly IV infusion. Note: abatacept cannot be combined with etanercept (contraindicated).

Secukinumab (Cosentyx) — IL-17A inhibitor; often preferred for ankylosing spondylitis and psoriatic arthritis; also covers plaque psoriasis.

Ustekinumab (Stelara) — IL-12/23 inhibitor; approved for PsA and plaque psoriasis; given every 12 weeks; biosimilars now available.

Tocilizumab (Actemra) — IL-6 receptor blocker; approved for RA when TNF inhibitors have failed.

JAK Inhibitors: Oral Options for RA and PsA

Janus kinase (JAK) inhibitors are oral pills that target a different inflammatory pathway than TNF inhibitors. FDA-approved options include tofacitinib (Xeljanz), baricitinib (Olumiant), and upadacitinib (Rinvoq) for RA; upadacitinib and tofacitinib are also approved for PsA and AS. These carry their own safety considerations (boxed warnings for serious infections, blood clots, and malignancy risk in older patients) and are generally used after inadequate response to biologics like etanercept.

Conventional DMARDs: The Lower-Cost Foundation

If cost is the primary concern and your disease allows it, conventional disease-modifying antirheumatic drugs (DMARDs) are far less expensive. Methotrexate is the most commonly used and costs as little as $10-$30 per month with generic pricing. Other options include hydroxychloroquine (Plaquenil), sulfasalazine, and leflunomide (Arava). These are typically used for milder disease or in combination with biologics.

Talking to Your Doctor About Switching

Switching biologic therapies is a decision that requires careful consideration of your disease history, insurance coverage, and individual risk factors. When you meet with your rheumatologist or dermatologist, bring:

Documentation of why etanercept is inaccessible (PA denial letter, cost, etc.)

Your insurance formulary to check which biologics are covered at what tier

A list of alternatives you're interested in and questions about the differences

Also consider exploring savings programs before switching — you may be able to make etanercept work financially. See our guide on how to save money on etanercept for more details.

And if you simply need help finding a pharmacy that has etanercept in stock, medfinder can search pharmacies near you on your behalf.